October 23, 2024
The Brits could have done better
UK-based pharmaphorum is covering the GLP-1 issue on this side of the pond — specifically Lilly’s and Novo’s rather silly contention that the injections are difficult to compound.
While it quoted Scott pointing out how Novo is deliberately conflating creating the semaglutide molecule with compounding with it, it used the weasel-word “claimed” rather than “said.” Still, we’ll take the international coverage.
